Skip to main
PGEN

Precigen (PGEN) Stock Forecast & Price Target

Precigen (PGEN) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precigen is a pharmaceutical company that focuses on developing precision medicines through its proprietary and complementary technology platforms, targeting immuno-oncology, autoimmune disorders, and infectious diseases. The company's key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. With its clinical pipeline, the company has a positive outlook for its PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007 programs. The recent approval and market exclusivity granted to its product Papzimeos in the treatment of adult recurrent respiratory papillomatosis (RRP) in the US market until August 2032, along with its strong launch and sales trajectory, reinforces the company's potential and ability to dominate this niche area. Precigen's cash flow breakeven by the end of 2026 also shows the company's financial stability, further supporting its positive outlook for investors.

Bears say

Precigen is actively pursuing label expansion opportunities through ongoing clinical trials, with management expecting that updated data from the Papzimeos pivotal trial at ASCO will support this. Additionally, the upcoming RRP Awareness Day in June, the first since PAPZIMEOS approval, is seen as a key opportunity to drive awareness and education of the product. Despite lowering the discount rate, the company is projecting a significant decline in its revenues and profits by 2027, likely due to increased competition in the immuno-oncology market and slower-than-expected adoption of its products.

Precigen (PGEN) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precigen (PGEN) Forecast

Analysts have given Precigen (PGEN) a Buy based on their latest research and market trends.

According to 3 analysts, Precigen (PGEN) has a Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precigen (PGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.